Grund Nicholas 4

What Happened
Nicholas Grund, Chief Commercial Officer of Akebia Therapeutics (AKBA), received equity awards on January 30, 2026: 204,000 restricted stock units (RSUs) and 320,000 derivative awards (stock options), both reported at $0. These are grants/awards (transaction code A) — compensation, not open-market purchases or sales.

Key Details

• Transaction date: 2026-01-30; Form 4 filed 2026-02-03 (filed within the SEC’s two-business-day window).
• Awards reported: 204,000 RSUs (reported acquisition value $0) and 320,000 derivative awards/options (reported $0).
• Shares owned after transaction: not specified in the provided Form 4 summary.
• Footnotes:
  • RSU vesting (F1): granted under the 2023 Stock Incentive Plan; vesting in three equal annual installments (one-third each year) subject to continued service.
  • Options vesting (F2): granted under the 2023 Stock Incentive Plan; vest over four years — 25% at the first anniversary, then remaining 75% in equal quarterly installments, subject to continued service.
• No exercise or sale occurred; these are grant awards (not cashless exercises or market sales).

Context
Grants like RSUs and options are common executive compensation and don’t represent an immediate buy or sell of shares. Options are rights to purchase shares in the future (they’re not exercised here); RSUs convert to shares as they vest. Because the filing does not show an exercise price or immediate sale, there is no immediate cash flow or change in public float from these entries.